Trade Summary

3 days ago, Kakkis Emil D, serving as Pres, CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 54,404 shares at $22.80 per share, for a total transaction value of $1,240,411.00. Following this transaction, Kakkis Emil D now holds 2,817,979 shares of RARE.

This sale represents a 2.00% decrease in Kakkis Emil D's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 3, 2026, 1 day after the trade was made.

Ultragenyx Pharmaceutical Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.